Bruce Booth sold $9.3M of SION
director at Sionna Therapeutics, Inc.. 286,369 shares at an average of $32.30, traded Oct 16, 2025, filed Oct 20, 2025.
Score components
- +15RoleDirector
- +25Trade size$9.3M at market
- +5Share of holdings soldSold 11% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001451612-25-000010, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 16, 2025 | SOpen-market sale Common Stockindirect: By Atlas Venture Fund XI, L.P.10b5-1 | -8,596 | $30.15 | $259k | 2,610,589 | Oct 20, 2025 |
| Oct 16, 2025 | SOpen-market sale Common Stockindirect: By Atlas Venture Opportunity Fund II, L.P.10b5-1 | -1,804 | $30.15 | $54k | 749,860 | Oct 20, 2025 |
| Oct 16, 2025 | SOpen-market sale Common Stockindirect: By Atlas Venture Fund XI, L.P.10b5-1 | -45,117 | $31.69 | $1.4M | 2,565,472 | Oct 20, 2025 |
| Oct 16, 2025 | SOpen-market sale Common Stockindirect: By Atlas Venture Opportunity Fund II, L.P.10b5-1 | -9,470 | $31.69 | $300k | 740,390 | Oct 20, 2025 |
| Oct 16, 2025 | SOpen-market sale Common Stockindirect: By Atlas Venture Fund XI, L.P.10b5-1 | -73,296 | $32.84 | $2.4M | 2,492,176 | Oct 20, 2025 |
| Oct 16, 2025 | SOpen-market sale Common Stockindirect: By Atlas Venture Opportunity Fund II, L.P.10b5-1 | -15,384 | $32.84 | $505k | 725,006 | Oct 20, 2025 |
| Oct 16, 2025 | SOpen-market sale Common Stockindirect: By Atlas Venture Fund XI, L.P.10b5-1 | -12,888 | $33.38 | $430k | 2,479,288 | Oct 20, 2025 |
| Oct 16, 2025 | SOpen-market sale Common Stockindirect: By Atlas Venture Opportunity Fund II, L.P.10b5-1 | -2,705 | $33.38 | $90k | 722,301 | Oct 20, 2025 |
| Oct 17, 2025 | SOpen-market sale Common Stockindirect: By Atlas Venture Fund XI, L.P.10b5-1 | -28,821 | $32.10 | $925k | 2,450,467 | Oct 20, 2025 |
| Oct 17, 2025 | SOpen-market sale Common Stockindirect: By Atlas Venture Opportunity Fund II, L.P.10b5-1 | -6,049 | $32.10 | $194k | 716,252 | Oct 20, 2025 |
| Oct 17, 2025 | SOpen-market sale Common Stockindirect: By Atlas Venture Fund XI, L.P.10b5-1 | -21,451 | $32.71 | $702k | 2,429,016 | Oct 20, 2025 |
| Oct 17, 2025 | SOpen-market sale Common Stockindirect: By Atlas Venture Opportunity Fund II, L.P.10b5-1 | -4,503 | $32.71 | $147k | 711,749 | Oct 20, 2025 |
| Oct 17, 2025 | SOpen-market sale Common Stockindirect: By Atlas Venture Fund XI, L.P.10b5-1 | -248 | $33.47 | $8,301 | 2,428,768 | Oct 20, 2025 |
| Oct 17, 2025 | SOpen-market sale Common Stockindirect: By Atlas Venture Opportunity Fund II, L.P.10b5-1 | -52 | $33.47 | $1,740 | 711,697 | Oct 20, 2025 |
| Oct 20, 2025 | SOpen-market sale Common Stockindirect: By Atlas Venture Fund XI, L.P.10b5-1 | -20,485 | $31.79 | $651k | 2,408,283 | Oct 20, 2025 |
| Oct 20, 2025 | SOpen-market sale Common Stockindirect: By Atlas Venture Opportunity Fund II, L.P.10b5-1 | -4,300 | $31.79 | $137k | 707,397 | Oct 20, 2025 |
| Oct 20, 2025 | SOpen-market sale Common Stockindirect: By Atlas Venture Fund XI, L.P.10b5-1 | -25,788 | $32.33 | $834k | 2,382,495 | Oct 20, 2025 |
| Oct 20, 2025 | SOpen-market sale Common Stockindirect: By Atlas Venture Opportunity Fund II, L.P.10b5-1 | -5,412 | $32.33 | $175k | 701,985 | Oct 20, 2025 |
Related signals
Other insiders at Sionna Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | SIONsell Sionna Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $22M 3,448,811 shares | -50% | |
| 15Weak | Sionna Therapeutics, Inc. | Jennifer Fitzpatrick Chief Legal Officer | $347k 10,250 shares | -100% | |
| 37Weak | SIONsell Sionna Therapeutics, Inc. | Tpg Gp A, LLC owner | $10M 250,000 shares | -4% | |
| 28Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $1.5M 33,356 shares | -1% | |
| 28Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $1.5M 33,356 shares | -1% | |
| 19Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $83k 1,875 shares | -0% | |
| 19Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $83k 1,875 shares | -0% | |
| 31Weak | Sionna Therapeutics, Inc. | Jennifer Fitzpatrick Chief Legal Officer | $415k 10,250 shares | -100% | |
| 35Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $4.8M 108,073 shares | -3% | |
| 35Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $4.8M 108,073 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.